Well, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
Arquer Diagnostics: New head for Dx
AppointmentsNovo Nordisk: Passing the baton
AppointmentsLars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development at Novo Nordisk, will take over the helm of the Danish diabetes major. He takes over from long-time CEO Lars Rebien Sørensen.
Bioplastics industry grapples with ignorant consumers
Latest NewsEU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin.
Real World Data: Beyond clinical trials
BackgroundOnly a small fraction of carefully selected patients are allowed to enroll in randomised controlled trials involving new compounds – the gold standard of drug assessment. But trying to acquire the most significant efficacy and safety results for a new drug is one goal, treating patients every day in hospitals or practices with it is something else entirely. Discrepancies are inevitable. Now real-world data that’s been gathered in large observational studies is attempting to close the gap between experimental, artificial study settings and clinical realities.
Carbios tackles marine littering
Latest NewsFrench Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans.
Neovacs teams up with 3P
Latest NewsFrench immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology.
Kymab raises €94m for mAb pipeline
Latest NewsUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing.
From randomised and controlled to clinical reality
OpinionThe randomised clinical trial (RCT) is the gold standard for drug evaluation. RCTs provide the core for drug development and subsequent drug approval often in the form of rigorously designed efficacy trials in carefully selected subjects. In fact, in- and exclusion criteria are often so restrictive that only 17% of patients from outpatient clinics would be eligible for trials in asthma and chronic obstructive pulmonary disease (COPD).
And the world turns
OpinionWell, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
Proteros inks US$167m oncology pact with MSD
Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.